Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity

Cancer Letters

Volumn 294, Issue 1, 2010, Pages 66-73

  Lv, Ming ^a   Lin, Zhou ^a   Qiao, Chunxia ^a   Gen, Shusheng ^b   Lang, Xiaoling ^b   Li, Yan ^a   Feng, Jiannan ^a   Shen, Beifen ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b Beijing Development Area   (China)

Author keywords

ADCC; Anti CD20 monoclonal antibody; Immunotherapy; Rituximab; TGLA

Indexed keywords

CD20 ANTIBODY; CD20 ANTIBODY TGLA; CHIMERIC ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CHO CELLS; CRICETINAE; CRICETULUS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; LYMPHOMA; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEPRILYSIN; OVARY;

EID: 77953023426     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.01.023     Document Type: Article

References (25)

1. Tedder T.F., Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994, 15:450-454.
2. Maloney D.G. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 2005, 23:6421-6428.
3. Martin P., Furman R.R., Ruan J., Elstrom R., Barrientos J., Niesvizky R., Coleman M., Leonard JP Novel, engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma Semin Hematol. 2008, 45(2):126-132. Apr.
4. Glennie M.J., van de Winkel J.G. Renaissance of cancer therapeutic antibodies. Drug Discov Today 2003, 8:503-510.
5. Leget G.A., Czuczman M.S. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998, 10:548-551.
6. Sharkey R.M., Goldenberg D.M. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006, 56:226-243.
7. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
8. Maloney D.G., Grillo-López A.J., Bodkin D.J., et al. IDECC2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997, 15:3266-3274.
9. Marcus R., Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol Suppl. 2007, 67(Jan):5-14.
10. Taylor R.P., Lindorfer M.A. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol. 2008, 20(4):444-449. Aug.
11. Glennie M.J., French R.R., Cragg M.S., Taylor R.P. Mechanism of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007, 44:3823-3837.
12. Golay J., Gramigna R., Facchinetti V., Capello D., Introna M. Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. Br J Haematol 2002, 119:923-929.
13. Natsume A, Shimizu-Yokoyama Y, Satoh M, Shitara K, Niwa R.Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity. Cancer Sci. 2009 Aug 25. [Epub ahead of print].
14. Nishida M., Usuda S., Okabe M., Miyakoda H., Komatsu M., Hanaoka H., Teshigawara K., Niwa O. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). Int J Oncol. 2007, 31(1):29-40. Jul.
15. Li B., Shi S., Qian W., Zhao L., Zhang D., Hou S., Zheng L., Dai J., Zhao J., Wang H., Guo Y. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res. 2008, 68(7):2400-2408. Apr 1.
16. Rossi E.A., Goldenberg D.M., Cardillo T.M., Stein R., Wang Y., Chang C.H. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res. 2008, 68(20):8384-8392. Oct 15.
17. Huang Y., Li Y., Wang Y.G., Gu X., Wang Y., Shen B.F. An efficient and targeted gene integration system for high-level antibody expression. J Immunol Methods. 2007, 322(1-2):28-39. Apr 30.
18. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446.
19. Di Gaetano N., Cittera E., Nota R., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003, 171:1581-1587.
20. Kennedy A.D., Beum P.V., Solga M.D., et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004, 172:3280-3288.
21. Cartron G., Dacheux L., Salles G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 2002, 99:754-758.
22. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940-3947.
23. Stowell C.P. J Infus Nurs. 2006, 29(3 Suppl):S29-44. Therapy with immunoglobulin: applications for monoclonal antibodies, May-Jun.
24. Plosker G.L., Figgitt D.P. Drugs. 2003, 63(8):803-843. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
25. Chatenoud L. Clin Transplant. 1993, 7(4 Pt 2):422-430. Immunologic monitoring during OKT 3 therapy, Aug.